Julia Currie is building a legal practice focused on capital markets and securities law. Her practice encompasses a broad range of corporate and commercial matters, including corporate finance, mergers and acquisitions, continuous disclosure obligations, and general corporate governance matters for public and private companies.
Julia joined McMillan as a summer student in 2022 and completed her articles at the firm before being called to the British Columbia bar in 2024. Julia graduated from the Juris Doctor program at the University of Alberta (UAlberta) Faculty of Law.
During her time at UAlberta, Julia was a panel member of the University Appeal Board where she reviewed disciplinary decisions relating to academic and student affairs. Julia also worked on behalf of Dean Barbara Billingsley as the Co-Chair of the Women in Law Speaker Series. Prior to law school, Julia obtained a Bachelor of Commerce (with distinction) from the UAlberta School of Business.
CSA issues guidance for non-investment fund reporting issuers on AI disclosure in capital markets, emphasizing transparency, risk factors, and compliance.
On August 1, 2024, proposed changes were published to revise the definition of "venture issuer" and transform the CSE Senior Tier into a non-venture exchange.
Canadian Securities Administrators have adopted an optional "access equals delivery" model for prospectuses of reporting issuers that are not investment funds.
Bright Minds Bioscience Inc. (CSE: DRUG, NASDAQ: DRUG) has closed a USD $35 million non-brokered private placement on November 4, 2024, issuing 1,612,902 common shares at USD $21.70 per share.
Get updates delivered right to your inbox. You can unsubscribe at any time.
236.826.3055